|
Sign In to gain access to subscriptions and/or personal tools.
|
Lupus, Vol. 12, No. 10,
779-782 (2003)
DOI: 10.1191/0961203303lu449cr
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy
R Weide
Haematology/Oncology Group Practice, Koblenz, Germany, Haem.Onc.Ko{at}t-online.de
J Heymanns
Haematology/Oncology Group Practice, Koblenz, Germany
A Pandorf
Haematology/Oncology Group Practice, Koblenz, Germany
H Köppler
Haematology/Oncology Group Practice, Koblenz, Germany
Systemic lupus erythematosus(SLE) is a chronic, inflammatory autoimmune disease that may involve multiple organ systems. Treatment consists of immunosuppression, cytotoxic treatment, plasmapheresis and immunoglobuline therapy. Treatment of patients refractory to standard treatment approaches is difficult and results are poor. We describe a 39-year old patient with SLE sufferingfrom grand mal epilepsy due to cerebralvasculopathywith positivelupus anticoagulant, who was refractory to standard treatment modalities. The patient was treated with the anti-CD20 monoclonal antibody rituximab (375 mg/m2 x4, repeated at weekly intervals). Rituximab applications were delivered in October 2000, March 2001 and October 2001. Since March 2002 she has received maintenance therapy with rituximab 375 mg/m2 every three months. A second female with refractory SLE was treated successfully in April 2002 and receives maintenance therapy every three months. Both patients responded well to rituximab therapy. The first patient showed a major improvement of her clinical condition, and 30 months after the beginning of the rituximab therapy she is free of any symptoms. inflammation parameters, ANA and lupus anticoagulantdeclined significantly after the treatment. The clinical conditionof the second patient improved dramatically, all inflammation parameters normalized and her circulating immunocomplexes disappeared. In conclusion, rituximab maintenance treatment may be a new effective therapy in SLE.
Key Words: maintenance therapy • rituximab • SLE
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Mihaylova, E. Voynova, A. Tchorbanov, M. Nikolova, A. Michova, T. Todorov, L. Srebreva, H. Taskov, and T. Vassilev
Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc{gamma}IIb receptor
Int. Immunol.,
February 1, 2008;
20(2):
165 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G.L. Erre, S. Pardini, R. Faedda, and G. Passiu
Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature
Lupus,
January 1, 2008;
17(1):
50 - 55.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Tokunaga, K. Saito, D. Kawabata, Y. Imura, T. Fujii, S. Nakayamada, S. Tsujimura, M. Nawata, S. Iwata, T. Azuma, et al.
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system
Ann Rheum Dis,
April 1, 2007;
66(4):
470 - 475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Haroon, D. O'Gradaigh, and D. Foley-Nolan
A case of Raynaud's phenomenon in mixed connective tissue disease responding to rituximab therapy
Rheumatology,
April 1, 2007;
46(4):
718 - 719.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. P. Carroll, F. Brown, and P. G. Kerr
Anti-CD20 antibody treatment in refractory Class IV lupus nephritis
Nephrol. Dial. Transplant.,
January 1, 2007;
22(1):
291 - 293.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Williams, J. J. Densmore, A. W. Pawluczkowycz, P. V. Beum, A. D. Kennedy, M. A. Lindorfer, S. H. Hamil, J. C. Eggleton, and R. P. Taylor
Thrice-Weekly Low-Dose Rituximab Decreases CD20 Loss via Shaving and Promotes Enhanced Targeting in Chronic Lymphocytic Leukemia
J. Immunol.,
November 15, 2006;
177(10):
7435 - 7443.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K P Ng, M J Leandro, J C Edwards, M R Ehrenstein, G Cambridge, and D A Isenberg
Repeated B cell depletion in treatment of refractory systemic lupus erythematosus
Ann Rheum Dis,
July 1, 2006;
65(7):
942 - 945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Quartuccio, G. Soardo, G. Romano, F. Zaja, C. A. Scott, G. De Marchi, M. Fabris, G. Ferraccioli, and S. De Vita
Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids
Rheumatology,
July 1, 2006;
45(7):
842 - 846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Risselada and C. G. M. Kallenberg
Therapy-resistent lupus skin disease successfully treated with rituximab
Rheumatology,
July 1, 2006;
45(7):
915 - 916.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Saito, M. Nawata, S. Iwata, M. Tokunaga, and Y. Tanaka
Extremely high titer of anti-human chimeric antibody following re-treatment with rituximab in a patient with active systemic lupus erythematosus
Rheumatology,
November 1, 2005;
44(11):
1462 - 1464.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J-E Gottenberg, L Guillevin, O Lambotte, B Combe, Y Allanore, A Cantagrel, C Larroche, M Soubrier, L Bouillet, M Dougados, et al.
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Ann Rheum Dis,
June 1, 2005;
64(6):
913 - 920.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raptopoulou, P. Sidiropoulos, and D. T Boumpas
Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus
Lupus,
December 1, 2004;
13(12):
887 - 890.
[PDF]
|
|
|
|
|
|
|
A. D. Kennedy, P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor
Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia
J. Immunol.,
March 1, 2004;
172(5):
3280 - 3288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
